Keyphrases
Haploidentical Hematopoietic Stem Cell Transplantation
59%
Post-transplantation Cyclophosphamide (PTCy)
57%
Peripheral Blood
49%
Haploidentical Transplantation
44%
Graft-versus-host Disease (GvHD)
37%
Haploidentical
37%
Acute Myeloid Leukemia
31%
Hematopoietic Cell Transplantation
24%
Hematopoietic Cell Transplant
24%
Multiple Myeloma
19%
Overall Survival
17%
HLA Matching
16%
Cytokine Release Syndrome
16%
Transplantation
15%
Unrelated Donor
15%
Co-stimulatory Domain
14%
Chimeric Antigen Receptor T Cells (CAR-T)
14%
T Cell Depletion
14%
Peripheral Blood Stem Cell Graft
14%
Confidence Interval
13%
Retrospective Analysis
10%
Haploidentical Donor
10%
Pretransplant
9%
Adjusted Hazard Ratio
9%
Acute Lymphoblastic Leukemia
9%
Matched Unrelated
9%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Donor Type
9%
Donor-recipient Matching
9%
Retrospective Cohort Study
8%
Complete Remission
8%
Leukemia Patients
8%
Non-associated
8%
Propensity Score Analysis
8%
Reduced Intensity
8%
High-dose Cyclophosphamide
8%
Disease-free Survival
8%
Myeloablative Conditioning
7%
Tocilizumab
7%
Reduced-intensity Conditioning
7%
Cutaneous Graft-versus-host Disease
7%
CD123
7%
Venous Thromboembolism Risk
7%
Elotuzumab
7%
Pomalidomide
7%
Remobilization
7%
Hematopoietic Transplant
7%
PIRCHE
7%
Donor Relationships
7%
Bortezomib
7%
Immunology and Microbiology
Hematopoietic Cell
100%
Cell Transplantation
73%
Cyclophosphamide
53%
Myeloid
31%
Cytokine Release Syndrome
22%
Graft-Versus-Host Disease
21%
T Cell
20%
Engraftment
17%
Peripheral Blood Stem Cell
17%
Acute Graft Versus Host Disease
16%
Conditioning
15%
Epitope
14%
Chimeric Antigen Receptor
14%
Overall Survival
12%
Chronic Graft Versus Host Disease
9%
Drug Megadose
8%
Tocilizumab
7%
Multiple Myeloma
7%
CD34
7%
Hemocyte
7%
Lenalidomide
7%
Dexamethasone
7%
Hematopoietic Stem Cell Transplantation
7%
Blood Flow
7%
Morbidity
7%
Human Leukocyte Antigen
7%
Lung Transplantation
7%
Acute Graft Rejection
7%
Bispecific Antibody
7%
Intravenous Immunoglobulin
7%
Plasmapheresis
7%
HLA Antibody
7%
Lymphocyte
7%
Allograft
7%
Antibodies
7%
Disease Free Survival
6%
Neutrophil
6%
Cytokine
5%
Medicine and Dentistry
Hematopoietic Cell
30%
Transplantation
23%
Cell Transplantation
22%
Multiple Myeloma
22%
Cyclophosphamide
22%
Dexamethasone
14%
Acute Lymphoblastic Leukemia
14%
Chimeric Antigen Receptor
14%
T Cell
14%
Peripheral Blood Stem Cell
14%
Graft Versus Host Reaction
11%
Acute Myeloid Leukemia
9%
B-Cell Lymphoma
7%
Cytokine Release Syndrome
7%
Multivariate Analysis
7%
Light Chain
7%
Lenalidomide
7%
Elotuzumab
7%
Acute Leukemia
7%
Pomalidomide
7%
Haploidentical Transplantation
7%
Venous Thromboembolism
7%
Bortezomib
7%
Carfilzomib
7%
Kidney Function
7%
Chimeric Antigen Receptor T-Cell Therapy
7%
Autotransplantation
7%
Human Leukocyte Antigen
7%
Donor Lymphocyte Infusion
7%
Lung Transplantation
7%
Cell Free DNA
7%
Myelodysplastic Syndrome
7%
Progression Free Survival
5%